{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:53:21Z","timestamp":1790016801931,"version":"4.0.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007184","name":"Yale School of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007184","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.antiviral.2020.104948","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T20:03:02Z","timestamp":1600977782000},"page":"104948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Tenofovir alafenamide does not inhibit mitochondrial function and cholesterol biosynthesis in human T lymphoblastoid cell line"],"prefix":"10.1016","volume":"183","author":[{"given":"Min","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold G.","family":"Dorsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Musoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dereck Amakye","family":"Jnr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5902-8660","authenticated-orcid":false,"given":"Natalie","family":"Schoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5949-9761","authenticated-orcid":false,"given":"Kweku","family":"Djan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah","family":"Paintsil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104948_bib1","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/jac\/dkn097","article-title":"Changes in metabolic toxicity after switching from stavudine\/didanosine to tenofovir\/lamivudine--a Staccato trial substudy","volume":"61","author":"Ananworanich","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2020.104948_bib2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32835192ae","article-title":"Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents","volume":"26","author":"Bedimo","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2020.104948_bib3","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1016\/S2352-3018(15)00181-2","article-title":"Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001\/ANRS143 randomised trial","volume":"2","author":"Bernardino","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.antiviral.2020.104948_bib4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1128\/AAC.01834-15","article-title":"Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors","volume":"60","author":"Birkus","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104948_bib5","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.46.3.716-723.2002","article-title":"Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors","volume":"46","author":"Birkus","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104948_bib6","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/mol.108.045526","article-title":"Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases","volume":"74","author":"Birkus","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2020.104948_bib7","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20110162","article-title":"Assessing mitochondrial dysfunction in cells","volume":"435","author":"Brand","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.antiviral.2020.104948_bib8","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0140-6736(99)06102-4","article-title":"Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy","volume":"354","author":"Brinkman","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2020.104948_bib9","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1016\/S0021-9258(18)80156-9","article-title":"Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine","volume":"264","author":"Chen","year":"1989","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2020.104948_bib10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0026-895X(25)11067-5","article-title":"Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity","volume":"39","author":"Chen","year":"1991","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.antiviral.2020.104948_bib11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1086\/655681","article-title":"Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients","volume":"51","author":"Cooper","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104948_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","article-title":"Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)","volume":"119","author":"De Clercq","year":"2016","journal-title":"Biochem. Pharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.antiviral.2020.104948_bib13","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1093\/infdis\/171.Supplement_2.S99","article-title":"Clinical pharmacokinetics of nucleoside antiretroviral agents","volume":"171","author":"Dudley","year":"1995","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104948_bib14","doi-asserted-by":"crossref","first-page":"E1666","DOI":"10.1152\/ajpendo.00550.2006","article-title":"Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults","volume":"292","author":"Fleischman","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metabol."},{"key":"10.1016\/j.antiviral.2020.104948_bib15","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/jac\/dkv098","article-title":"Efavirenz alters mitochondrial respiratory function in cultured neuron and glial cell lines","volume":"70","author":"Funes","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2020.104948_bib16","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/jac\/dkv098","article-title":"Efavirenz alters mitochondrial respiratory function in cultured neuron and glial cell lines","volume":"70","author":"Funes","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2020.104948_bib17","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1097\/QAD.0b013e3283112b8e","article-title":"The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients","volume":"22","author":"Gallant","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2020.104948_bib18","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00467-012-2269-7","article-title":"Update on tenofovir toxicity in the kidney","volume":"28","author":"Hall","year":"2013","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.antiviral.2020.104948_bib19","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.tiv.2005.11.007","article-title":"Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity","volume":"20","author":"Hoschele","year":"2006","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.antiviral.2020.104948_bib20","doi-asserted-by":"crossref","first-page":"40847","DOI":"10.1074\/jbc.M106743200","article-title":"Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase","volume":"276","author":"Johnson","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2020.104948_bib21","series-title":"Nephrotoxicity of HAART. AIDS Research and Treatment 2011","first-page":"562790","author":"Kalyesubula","year":"2011"},{"key":"10.1016\/j.antiviral.2020.104948_bib22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nm0595-417","article-title":"Mitochondrial toxicity of antiviral drugs","volume":"1","author":"Lewis","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2020.104948_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00691-18","article-title":"Combination of tenofovir and emtricitabine with efavirenz does not moderate inhibitory effect of efavirenz on mitochondrial function and cholesterol biosynthesis in human T lymphoblastoid cell line","author":"Li","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104948_bib24","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/01.aids.0000233574.49220.de","article-title":"Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir","volume":"20","author":"Llibre","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2020.104948_bib25","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3727\/000000006783980892","article-title":"Expression of MDR1 in epithelial ovarian cancer and its association with disease progression","volume":"16","author":"Lu","year":"2007","journal-title":"Oncol. Res."},{"key":"10.1016\/j.antiviral.2020.104948_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1023\/A:1022945107762","article-title":"The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update","volume":"8","author":"Ly","year":"2003","journal-title":"Apoptosis"},{"key":"10.1016\/j.antiviral.2020.104948_bib27","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1086\/429697","article-title":"In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA","volume":"191","author":"Mallon","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104948_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.antiviral.2016.05.012","article-title":"High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate","volume":"132","author":"Margot","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104948_bib29","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1128\/AAC.38.12.2743","article-title":"Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis","volume":"38","author":"Martin","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104948_bib30","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s10067-014-2627-x","article-title":"Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients","volume":"35","author":"Mateo","year":"2016","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.antiviral.2020.104948_bib31","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1128\/AAC.38.8.1824","article-title":"Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides","volume":"38","author":"Medina","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104948_bib32","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1097\/QAD.0000000000001572","article-title":"Tenofovir-induced toxicity in renal proximal tubular epithelial cells: involvement of mitochondria","volume":"31","author":"Mili\u00e1n","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2020.104948_bib33","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0000000000000618","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study","volume":"69","author":"Mills","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2020.104948_bib34","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1006\/geno.1997.4825","article-title":"Localization of the squalene epoxidase gene (SQLE) to human chromosome region 8q24.1","volume":"44","author":"Nagai","year":"1997","journal-title":"Genomics"},{"key":"10.1016\/j.antiviral.2020.104948_bib35","first-page":"3767","article-title":"ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma","volume":"8","author":"Ohishi","year":"2002","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.antiviral.2020.104948_bib36","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QAI.0000000000000908","article-title":"Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study","volume":"71","author":"Pozniak","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2020.104948_bib37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104948_bib38","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1158\/1078-0432.CCR-07-2061","article-title":"GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma","volume":"14","author":"Reiser","year":"2008","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.antiviral.2020.104948_bib39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40169-016-0106-5","article-title":"Mitochondria, cholesterol and cancer cell metabolism","volume":"5","author":"Ribas","year":"2016","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.antiviral.2020.104948_bib40","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults","volume":"63","author":"Ruane","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2020.104948_bib41","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2020.104948_bib42","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study","volume":"67","author":"Sax","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2020.104948_bib43","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/nrg3275","article-title":"Human mitochondrial DNA: roles of inherited and somatic mutations","volume":"13","author":"Schon","year":"2012","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.antiviral.2020.104948_bib44","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1089\/aid.2007.0262","article-title":"Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy status","volume":"24","author":"Shikuma","year":"2008","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.antiviral.2020.104948_bib45","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2017.01.014","article-title":"Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures","volume":"140","author":"Stray","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104948_bib46","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2017.01.014","article-title":"Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures","volume":"140","author":"Stray","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104948_bib47","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/QAD.0000000000001299","article-title":"Insulin resistance in HIV-infected youth is associated with decreased mitochondrial respiration","volume":"31","author":"Takemoto","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2020.104948_bib48","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/QAD.0b013e32833ad8b4","article-title":"A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206","volume":"24","author":"Tungsiripat","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2020.104948_bib49","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1093\/hmg\/ddh342","article-title":"Twinkle helicase is essential for mtDNA maintenance and regulates mtDNA copy number","volume":"13","author":"Tyynismaa","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.antiviral.2020.104948_bib50","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1177\/135965350701200704","article-title":"Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors","volume":"12","author":"Venhoff","year":"2007","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2020.104948_bib51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0022-1759(95)00072-I","article-title":"A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V","volume":"184","author":"Vermes","year":"1995","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.antiviral.2020.104948_bib52","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev.genet.39.110304.095751","article-title":"A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine","volume":"39","author":"Wallace","year":"2005","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.antiviral.2020.104948_bib53","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/QAI.0000000000000940","article-title":"Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 Re","volume":"72","author":"Wohl","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.antiviral.2020.104948_bib54","doi-asserted-by":"crossref","first-page":"46344","DOI":"10.1038\/srep46344","article-title":"Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220303624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354220303624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:33:07Z","timestamp":1759062787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354220303624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":54,"alternative-id":["S0166354220303624"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104948","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tenofovir alafenamide does not inhibit mitochondrial function and cholesterol biosynthesis in human T lymphoblastoid cell line","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104948","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104948"}}